Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M, Lee DH, Linker RA, Doerck S, Straeten V, Windhagen S, Pawlitzki M, Aufenberg C, Lang M, Eienbroeker C, Tackenberg B, Limmroth V, Wildemann B, Haas J, Klotz L, Wiendl H, Ruck T, Meuth SG.
Pfeuffer S, et al. Among authors: straeten fa.
J Neurol. 2019 Jan;266(1):165-173. doi: 10.1007/s00415-018-9117-z. Epub 2018 Nov 16.
J Neurol. 2019.
PMID: 30446966